Opendata, web and dolomites

PAVE SIGNED

A nanovaccine Approach for the treatment of Pancreatic Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PAVE" data sheet

The following table provides information about the project.

Coordinator
PERCUROS BV 

Organization address
address: PLESMANLAAN 1
city: LEIDEN
postcode: 2333 BZ
website: www.percuros.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 4˙023˙616 €
 EC max contribution 4˙023˙616 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2023-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PERCUROS BV NL (LEIDEN) coordinator 265˙619.00
2    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 531˙239.00
3    MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV DE (MUENCHEN) participant 505˙576.00
4    THE UNIVERSITY OF BIRMINGHAM UK (BIRMINGHAM) participant 303˙172.00
5    DANMARKS TEKNISKE UNIVERSITET DK (KGS LYNGBY) participant 297˙522.00
6    POLYPURE AS NO (OSLO) participant 292˙342.00
7    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 274˙802.00
8    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 265˙619.00
9    GOOD BIOMARKER SCIENCES BV NL (SASSENHEIM) participant 265˙619.00
10    TECHNISCHE UNIVERSITEIT DELFT NL (DELFT) participant 265˙619.00
11    KLINIKUM DER UNIVERSITAET REGENSBURG DE (REGENSBURG) participant 252˙788.00
12    TECHNISCHE UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 252˙788.00
13    UNIVERSITAT DE BARCELONA ES (BARCELONA) participant 250˙904.00

Map

 Project objective

A Nanovaccine Approach For The Treatment of Pancreatic Cancer By Multicomponent Immuno-Modulation: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in men and women and still fatal in over 90% of patients. It is characterised by its extremely aggressive nature where it is also responsible for the highest mortality rate compared to other major cancers, resulting in excess of 250,000 deaths worldwide per annum. Current state-of-art therapies for advanced PDAC including chemo- and/or radiotherapy, despite extensive efforts, have met with only limited success. Surgery is only applicable for those with early stages of the disease, or to relieve symptoms, if the cancer is blocking the bile duct or the bowel. There are two major reasons for the resistance of PDAC to conventional therapy. Firstly, PDAC has a very defining hallmark, where an abundance of stromal content is present in the tumour microenvironment (TME) to form a physical and biochemical barrier. Secondly, during progression of the disease, the body's immune system is hijacked to support the proliferation of the cancer. New approaches, such as immunotherapy, are therefore needed where it has already shown promise in overcoming many aspects of this resistance. Immunotherapy has the potential to treat minimal residual disease after pancreatic resection (surgery) as well as for metastatic and non-resectable PDAC. Our objective for this project is to bring together a multidisciplinary and intersectoral group to develop novel vaccine approaches, including use of multiple immunomodulating components.

 Publications

year authors and title journal last update
List of publications.
2020 Somayeh Rezaei, Soheila Kashanian, Yadollah Bahrami, Luis J. Cruz, Marjan Motiei
Redox-Sensitive and Hyaluronic Acid-Functionalized Nanoparticles for Improving Breast Cancer Treatment by Cytoplasmic 17α-Methyltestosterone Delivery
published pages: 1181, ISSN: 1420-3049, DOI: 10.3390/molecules25051181
Molecules 25/5 2020-04-15

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PAVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PAVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

GREAT (2019)

Grating Reflectors Enabled laser Applications and Training

Read More  

LIVE-I (2020)

Lightening and Innovating transmission for improving Vehicle: Environmental Impacts

Read More  

LongActNow (2019)

Long Acting Medicines for Complex Therapeutics Needed Now

Read More